Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $50.
October 12, 2023 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Surgery Partners and maintained a price target of $50.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $50 price target indicates a positive outlook for Surgery Partners. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100